tiprankstipranks

Peter Sonsini Insider Profile

11 Followers
Peter Sonsini, Ten Percent Owner at Arca Biopharma, holds 6.52M shares in Eargo (Ticker: EAR), holds 3.06M shares in Metacrine (Ticker: MTCR), holds 5.96M shares in Mersana Therapeutics (Ticker: MRSN).
tipranks
Peter Sonsini

Peter Sonsini
Arca Biopharma (ABIO)
Ten Percent Owner

Ranked #74,098 out of 78,624 Corporate Insiders

Profitable Transactions

25%
13 out of 52 Profitable Transactions

Average Return

-12.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$2B
33.17%
21.39%
9.87%
6.49%
29.09% Others
A breakdown of Peter Sonsini's holdings

Insider Roles

Adaptimmune Therapeutics
(ADAP)
Ten Percent Owner
Eargo
(EAR)
Ten Percent Owner
Mersana Therapeutics
(MRSN)
Ten Percent Owner
Nkarta
(NKTX)
Ten Percent Owner
+15 other positions
Roles that Peter Sonsini holds in companies

Most Profitable Insider Trade

Stock:
Achaogen
(AKAOQ)
Rating:Informative Buy
Date:Jun 07, 2016 - Jun 07, 2017
Return:+423.70%
The most profitable trade made by Peter Sonsini

Peter Sonsini's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Arca Biopharma
Feb 27, 2018
Ten Percent Owner
Informative Sell
730.10K
$0.00
Adaptimmune Therapeutics
Jan 28, 2020
Ten Percent Owner
Informative Buy
4.95M
$503.17M
AVEO Pharma
Jun 22, 2020
Ten Percent Owner
Informative Buy
7.50M
$21.39M
Achaogen
Dec 19, 2016
Ten Percent Owner
Informative Buy
6.75M
$47.15K
CASC
Cascadian Therapeutics
Mar 13, 2018
Uninformative Sell
$0.00
Regulus
May 09, 2019
Ten Percent Owner
Informative Buy
1.23M
$1.31M
Appian
Feb 15, 2018
Ten Percent Owner
Uninformative Buy
$196.78K
Synlogic
Jan 26, 2018
Ten Percent Owner
Uninformative Buy
4.00M
$10.57M
Surface Oncology
Apr 23, 2018
Ten Percent Owner
Uninformative Buy
$26.04M
MULE
Mulesoft Inc
May 09, 2018
Uninformative Sell
$0.00
Genocea Biosciences
Jul 28, 2020
Ten Percent Owner
Informative Buy
7.09M
$21.58M
Trevi Therapeutics
Apr 13, 2020
Ten Percent Owner
Uninformative Buy
1.50K
$18.32M
Mirum Pharmaceuticals
Jul 24, 2019
Ten Percent Owner
Uninformative Buy
$93.14M
Mersana Therapeutics
Sep 16, 2020
Ten Percent Owner
Uninformative Buy
$149.68M
AKOUOS
Jul 01, 2020
Ten Percent Owner
Uninformative Buy
$88.93M
Nkarta
Jul 16, 2020
Ten Percent Owner
Uninformative Buy
$98.38M
Inozyme Pharma
Jul 28, 2020
Ten Percent Owner
Uninformative Buy
$63.94M
Metacrine
Sep 22, 2020
Ten Percent Owner
Uninformative Buy
$23.72M
Eargo
Oct 22, 2020
Ten Percent Owner
Uninformative Buy
$324.37M
Ardelyx
Dec 09, 2019
Ten Percent Owner
Uninformative Buy
2.50M
$41.42M
TRACON Pharmaceuticals
Mar 27, 2018
Ten Percent Owner
Informative Buy
1.91M
$30.60M
LOXO
Loxo Oncology
Aug 06, 2014
Uninformative Buy
$419.91M
List of latest transactions for each holding click on a transaction to see Peter Sonsini's performance on stock

Peter Sonsini insider profile FAQ

What is the percentage of profitable transactions made by Peter Sonsini?
The percentage of profitable transactions made by Peter Sonsini is 25%.
    What is the average return per transaction made by Peter Sonsini?
    The average return per transaction made by Peter Sonsini is -12.70%.
      What stocks does Peter Sonsini hold?
      Peter Sonsini holds: ABIO, ADAP, AVEO, AKAOQ, CASC, RGLS, APPN, SYBX, SURF, MULE, GNCA, TRVI, MIRM, MRSN, AKUS, NKTX, INZY, MTCR, EAR, ARDX, TCON, LOXO stocks.
        What was Peter Sonsini’s latest transaction?
        Peter Sonsini latest transaction was an Uninformative Buy of ―.
          What was Peter Sonsini's most profitable transaction?
          Peter Sonsini’s most profitable transaction was an Informative Buy of AKAOQ stock on June 7, 2016. The return on the trade was 423.70%.
            What is Peter Sonsini's role in Arca Biopharma?
            Peter Sonsini's role in Arca Biopharma is Ten Percent Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.